anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Topical microbicides are designed to prevent the sexual transmission of HIV and other disease pathogens. PRO 2000/5 Gel (P), or PRO 2000, is a vaginal microbicide that has been evaluated in Phase I safety trials in Europe and the U.S. PRO 2000 Gel is easily manufactured, highly stable, and highly water-soluble. The aqueous gel formulation contains a synthetic carbomer, a lactic acid/lactate buffer, and preservatives. In vitro, PRO 2000 Gel has been shown to suppress infection by herpes viruses, Chlamydia trachomatis, Neisseria gonorrhoeae, and a wide range of HIV-1 isolates. This study will evaluate the safety and acceptability of PRO 2000 Gel in HIV uninfected women in Pune, India. The study is a precursor to a larger Phase II/III study of PRO 2000 Gel.

Participants in this study will be sexually active HIV uninfected women at either low or high risk for HIV infection. Male partners of these women will also be enrolled in the study. Participants will be asked to apply PRO 2000 Gel twice a day for 14 consecutive days between menses and to have vaginal intercourse with a single male partner, using study-provided male condoms, at least twice per week during the two weeks of PRO 2000 Gel use. Participants will have a screening visit, an enrollment visit, and 3 study visits during the two weeks of PRO 2000 Gel use; each visit will last about 1 hour. Study visits will include a medical history, gynecologic exam, blood and urine tests, and product acceptability questionnaires. Colposcopy will be performed three times during the study. Participants will also be asked to complete a Daily Study Record about product use and sexual activity and questionnaires about their willingness to use the product and their perceptions of the product.

Four weeks after using PRO 2000 Gel, participants will be asked to participate in a focus group to discuss product acceptability. Participants' male partners will also be asked to participate in focus groups about product use.
This is a randomized, active-comparator, multicenter study consisting of 3 phases: a Pretreatment (Screening) Phase, a Treatment Phase, and a Posttreatment Phase. Subject eligibility will be determined at the screening visit based on signs and symptoms of acute otitis media (e.g., middle ear effusion, acute inflammation, acute purulent otorrhea) and criteria for recurrent and/or persistent acute otitis media. Eligible subjects will be randomized and drug will be dispensed by a study coordinator who will instruct parents and the subject about the importance of not revealing the assigned therapy to the subject's evaluator. Each subject will have an evaluator who will remain blinded to the subject's therapy throughout the study. Clinical assessments performed by a blinded evaluator at several time points throughout the study will be used to evaluate efficacy. Safety will be evaluated throughout the study by assessment of adverse events and changes in physical examinations (including musculoskeletal examination with evaluation of joints), vital signs, and clinical laboratory findings. Supplementary safety evaluations for musculoskeletal adverse events will be performed throughout the study. All subjects who enroll in this study and take at least 1 dose of levofloxacin or amoxicillin/clavulanate will be eligible to rollover into a long-term surveillance study primarily focused on the musculoskeletal system. The purpose of this study is to demonstrate non-inferiority of levofloxacin compared with amoxicillin/clavulanate on the clinical response at the end of therapy in infants and children who have recurrent and/or persistent acute otitis media. Either levofloxacin 10 mg/kg twice daily for 10 days (maximum daily dose of 500 mg) or amoxicillin/clavulanate (14:1) 45 mg amoxicillin/kg twice daily for 10 days (maximum daily dose of 3600 mg amoxicillin). Both study drugs will be given orally as a liquid suspension formulation
The present invention relates to a new oligonucleotide sequence inhibiting the activity of human tumor necrosis factor alpha (TNFalpha). The sequence comprises a DNA sequence and an RNA sequence. The oligonucleotide sequence, namely an adapter can be specifically combined with TNF alpha and can effectively inhibit the lethal effect of the TNF alpha on L929 cells. Therefore, the adapter of the present invention can be used for detecting TNF alpha and treating diseases caused by the level increase of TNF alpha. Compared with the existing TNF alpha antagonist, the adapter in the present invention has the advantages of high specificity, high affinity, rapid arrival to a target tissue, rapid plasma clearance, low immunogenicity, repeated use, high content maintenance in a target tissue, etc. The adapter has the affinity and the specificity of a monoclonal antibody and the permeability and the medicine generation kinetic property of small molecule polypeptide. The present invention also relates to a derive sequence of the oligonucleotide sequence comprising a decorated sequence and further relates to the application of the oligonucleotide sequence in the preparation of medicines for diagnosing or treating diseases related to TNF alpha.
The present invention relates to a milbemycin oxime and praziquantel flavor tablet and a preparation method therefor. The milbemycin oxime and praziquantel flavor tablet of the present invention consists of a tablet core and a drug-free coating layer coated on the surface of the tablet core. One or more coating layers can be present. The coating layer contains at least one phagostimulant or corrigent. The tablet core consists of a pellet, a glidant, and a lubricant. The preparation process of the milbemycin oxime and praziquantel flavor tablet of the present invention comprises drug-containing powder→micropellet→tablet core→coating layer→flavor tablet. The preparation process is simple, and can uniformly mix a main drug and assistants together, so that the assistants can better function, the stability of the drug is improved, the taste of the drug is improved, and the flavor tablet is suitable for industrial production, and has wide application prospects.
PURPOSE: Iatrogenic lip injury may occur during oral and maxillofacial surgical procedures. This study aimed to evaluate the effect of oral retractors on iatrogenic lip injury prevention during intraoral procedures of oral and maxillofacial surgery.
METHODS: We conducted a randomized controlled trial and included patients who underwent intraoral procedures of oral and maxillofacial surgery. Patients were randomly allocated to receive oral retractor (intervention group) or traditional procedure without lip protection (control group). The incidence of lip injury was the outcome variable. Other study variables included surgical time and satisfaction of patients and surgeons with treatment experience evaluated by visual analog scale (VAS). Student t test and χ 2 test were used to compare both groups' variables and measure the relationship between the predictor variable and the outcome variable. P <0.05 was considered significant for all analyses.
RESULTS: A total of 114 patients were included, with 56 allocated to intervention group and 58 to control group. The results showed that the application of an oral retractor did not significantly increase surgical time ( P =0.318). A total of 12 patients had lip injury, with 1 in the intervention group and 11 in the control group ( P =0.003). For the assessment of satisfaction with treatment experience, the intervention group had significantly higher VAS scores for doctors and patients ( P <0.05).
CONCLUSIONS: We found that the oral retractor was a good tool for iatrogenic lip injury prevention in oral and maxillofacial surgical procedures and could be considered in clinical treatment.
This study aims to evaluate the correlation between serum thyroid hormone levels and hepatitis B virus (HBV) DNA and HBV genotypes in pregnant women with chronic hepatitis B. A total of 96 pregnant women with chronic HBV-infected pregnant women between January 2020 and December 2022 were selected as the observational study subjects. About 50 HBV-uninfected pregnant women during the same period were selected as the control group. Serum thyroid hormone levels at different stages of pregnancy, including free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone (TSH), thyroperoxidase antibody (TPOAb), and thyroglobulin antibody (TGAb), were compared between the 2 groups. Thyroid hormones levels were also compared between HBV-DNA-positive and HBV-DNA-negative women in the HBV-infected pregnancy group, and to determine the correlation between thyroid hormones levels and HBV-DNA load and HBV genotype in HBV-DNA-positive pregnant women. The TSH levels in mid and late pregnancy and TPOAb levels in early, mid, and late pregnancy of HBV-infected pregnant women were higher than those in the same period in HBV-uninfected pregnant women (P < .05). The TPOAb and TGAb levels in early, mid, and late pregnancy of HBV-DNA-positive pregnant women were higher than those in the same period in HBV-DNA-negative pregnant women (P < .05). The HBV-DNA load and FT3 or FT4 levels were negatively correlated (P < .05), and the HBV-DNA load and TGAb levels were positively correlated (P < .05). However, there was no statistical difference in thyroid hormone levels between different HBV genotypes (P > .05). The thyroid hormone levels will change in pregnant women infected with hepatitis B virus, and there is a certain correlation between HBV-DNA load and thyroid hormone levels. Therefore, timely monitoring of thyroid hormones and HBV-DNA load can provide early prevention and treatment for HBV infection in pregnant women, ensuring the health of pregnant women and fetuses.
PROBLEM TO BE SOLVED: To obtain an antimicrobial agent exhibiting antibacterial action on bacteria such as Staphylococcus aureus and suppressed in irritation to skin by including aluminum magnesium silicate and aluminium silicate. SOLUTION: This antimicrobial agent comprises preferably 0.0005-100 wt.% aluminum magnesium silicate and/or aluminum silicate. The antimicrobial agent may be formed as any of liquid, powder, tablet, gel, etc., when the agent contains aluminum magnesium silicate and aluminium silicate and e.g. smectite (montmorillonite group mineral, representative mineral constituting clay) can be used. Furthermore, the smectite is selected from e.g. montmorillonite, magnesian montmorillonite, iron montmorillonite, iron magnesian montmorillonite, beidellite, aluminian beidellite, saponite, aluminian saponite and bentonite.
Healthcare appointment information system and method enabling a patient to manage multiple accounts with third party sources through a single account. A user account is created for storing individual user healthcare data such as user preferences (e.g., Monday morning appointments or willingness to be placed on waiting lists), user names and passwords (for accessing third-party sources), contact information (phone, email, text), insurance plans, gender, age, medications, existing appointments and other healthcare information enabling the system to book an appointment on behalf of the patient on one or more availability sources. In addition to booking on the patient's behalf, the account information also enables patient communications with the various sources to be conducted through the system. For example, notifications from other availability sources can be transmitted through the system, which may reformat the message and communicate the reformatted message to the patient. The patient response may then be transmitted via the system to the source. These communications or their content may also be used to update the user account information.
The invention relates to a use of Lathyranone A in preparation of a drug for promoting small intestine peristalsis. The invention provides the use of Lathyranone A in preparation of a drug for promoting small intestine peristalsis. A pharmacological experiment proves that Lathyranone A has good effects of promoting small intestine peristalsis. The use of the Lathyranone A in preparation of a drug for promoting small intestine peristalsis is disclosed first. The Lathyranone A has a novel skeleton type and has unexpected small intestine peristalsis promoting activity. The use of the Lathyranone A does not get any enlightenment from other compounds and has outstanding substantive features and substantial progress in small intestine peristalsis promoting.
NEW MATERIAL:The compound of the formula. USE:Preventive and remedy for microbism which is active against gram-positive and negative gacteria. PREPARATION:7-Amino-iodomethyl-4<3>-cephem-4-carboxylic aicd is allowed to react with N, O-bis(trimethylsilyl)trifluoroacetamide and 3-amino-4-methoxy- pyridine is added to reaction mixture to prepare I solution. Then, (Z)-d-(2-tritylamino-4<3>-thazolyl)-alpha-methoxyiminoacetic acid is suspended in dichloromethane and allowed to react with phosphorus pentachloride to prepare II solution. Then, the I solution is cooled, combined with pyridine, than allowed to react with the IIsolution to give the compound of the formula. The product has very high solubility in water and can ve used as an intramuscular injection solution. The dose is 250-3,000mg/day and its is given in portions 3-4 times a day. It can be given orally as well.
Numbers are presented in fixed frequency format only (5 out of 1000, 0.6 out of 1000). Denominators remains the same for each number.
In a portable terminal device, it is possible to display information of caller and the like when a call is received. Incoming call signal reception means (11) receives an incoming call signal including a caller number, caller information, and ring type information. Image generation means (12) generates, based on the incoming call signal, a caller information image including at least a portion of the caller information as character information. Telephone dictionary registering means (13) registers the caller number, caller text information, and the caller information image in a telephone dictionary (14). Incoming call screen display means (15) receives the caller number and acquires the registered caller text information and the caller information image corresponding to the received caller number from the telephone dictionary (14). Incoming call screen display means (15) displays an incoming call screen including the caller text information and the caller information image.
Participants will be asked to take home the investigational PAP system (Amalfi) to use at night while they sleep in place of their own PAP system. The participant's therapy and comfort settings will not be altered. Participants will be randomized as to the order they will trial PAP System A and PAP System B. This arm will first use the Amalfi for 7 days and then use the CLA 11 for 7 days.
Asthma is one of the most common chronic non-communicable diseases worldwide, characterized by variable airflow limitation secondary to airway narrowing, airway wall thickening, and increased mucus resulting from chronic inflammation and airway remodeling. Current epidemiological studies reported that hypovitaminosis D is frequent in patients with asthma and is associated with worsening the disease and that supplementation with vitamin D3 improves asthma symptoms. However, despite several advances in the field, the molecular mechanisms of asthma have yet to be comprehensively understood. MicroRNAs play an important role in controlling several biological processes and their deregulation is implicated in diverse diseases, including asthma. Evidence supports that the dysregulation of miR-21, miR-27b, miR-145, miR-146a, and miR-155 leads to disbalance of Th1/Th2 cells, inflammation, and airway remodeling, resulting in exacerbation of asthma. This review addresses how these molecular mechanisms explain the development of asthma and its exacerbation and how vitamin D3 may modulate these microRNAs to improve asthma symptoms.
Experience concerning injection of quinidine during recovery from use of other muscle relaxants suggests that recurrent paralysis may occur. This possibility must also be considered for vecuronium. Vecuronium induced neuromuscular blockade has been counteracted by alkalosis and enhanced by acidosis in experimental animals (cat). Electrolyte imbalance and diseases which lead to electrolyte imbalance, such as adrenal cortical insufficiency, have been shown to alter neuromuscular blockade. Depending on the nature of the imbalance, either enhancement or inhibition may be expected. Magnesium salts, administered for the management of toxemia of pregnancy may enhance the neuromuscular blockade.
Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
Maltodextrin (matches the weight of the active treatment). Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
Participants will receive 210 mg brodalumab subcutaneously at Week 0, Week 1, and Week 2, and then once every 2 weeks. \*Participants not fulfilling a predefined response at any visit with efficacy assessments after Week 16 will receive a dose adjustment to 280 mg brodalumab every 2 weeks.
A method of automatically diagnosing pneumonia in a patient includes using an input/output interface device to obtain values of two or more diagnostic parameters of the patient from a carer for the patient. The method includes using a processor coupled to the input/output interface to apply the two or more diagnostic parameters to an electronic memory storing a plurality of precompiled pneumonia diagnostic models to identify an optimal diagnostic model for making a diagnosis. The values of the two or more diagnostic signs are applied to the identified optimal diagnostic model to generate a diagnosis output. The input/output interface device is operated in accordance with the diagnosis output to indicate the presence or absence of pneumonia in the patient to the carer. The carer may use the diagnosis to provide appropriate care to the patient. The pneumonia diagnostic models are derived from investigation of a population of pneumonia positive and non-pneumonia subjects.
Antikaliuretic Therapy and Potassium Supplementation: Triamterene and hydrochlorothiazide capsules, USP should not be given to patients receiving other potassium-sparing agents such as spironolactone, amiloride, or other formulations containing triamterene. Concomitant potassium-containing salt substitutes should also not be used. 

Potassium supplementation should not be used with triamterene and hydrochlorothiazide capsules, USP except in severe cases of hypokalemia. Such concomitant therapy can be associated with rapid increases in serum potassium levels. If potassium supplementation is used, careful monitoring of the serum potassium level is necessary.

Impaired Renal Function: Triamterene and hydrochlorothiazide capsules, USP are contraindicated in patients with anuria, acute and chronic renal insufficiency, or significant renal impairment. 

Hypersensitivity: Hypersensitivity to either drug in the preparation or to other sulfonamide-derived drugs is a contraindication. 

Hyperkalemia: Triamterene and hydrochlorothiazide capsules, USP should not be used in patients with pre-existing elevated serum potassium.
1. Use of a physiologically acceptable vanadium compound as active component in the preparation of a pharmaceutical composition for the prophylactic treatment of secondary injury of tissue, said secondary injury being induced by primary injury of mainly surrounding tissue and being the result of a traumatic event. 2. Use according to Claim 1, wherein the pharmaceutical composition is administered in a single dose. 3. Use according to Claim 1 or Claim 2, wherein the pharmaceutical composition is administered before or immediately or shortly after the traumatic event. 4. Use according to Claim 3, wherein the pharmaceutical composition is administered within one week after the traumatic event. 5. Use according to any one of the preceding Claims, wherein the pharmaceutical composition is administered intravenously or orally. 6. Use according to any one of the preceding Claims, wherein the tissue is a transplant. 7. Use according to any one of the preceding Claims, wherein the traumatic event is surgery. 8. Use according to any one of the preceding Claims, wherein the tissue is non-proliferative tissue. 9. Use according to Claim 8, wherein the non-proliferative tissue is heart, kidney, liver, nervous or other differentiated tissue. 10. Use according to Claim 8 or Claim 9, wherein the traumatic event is ischaemia. 11. Use according to any one of Claims 1 to 7, wherein primary injury occurs to epidermal tissue. 12. Use according to any one of Claims 1 to 5 and 11, wherein the traumatic event is a burn. 13. Use according to Claim 12, wherein the tissue comprises a deep vascular plexus, hair bulbs and/or sweat glands. 14. Use according to any one of the preceding Claims, wherein the vanadium compound is an organovanadium compound. 15. Use according to Claim 14; wherein the vanadium compound is bis(maltolato)oxovanadium (IV) or the corresponding bis(maltolato)oxovanadate salt.
Valproate is metabolized almost entirely by the liver. In adult patients on monotherapy, 30-50% of an administered dose appears in urine as a glucuronide conjugate. Mitochondrial β-oxidation is the other major metabolic pathway, typically accounting for over 40% of the dose. Usually, less than 15-20% of the dose is eliminated by other oxidative mechanisms. Less than 3% of an administered dose is excreted unchanged in urine. 

The relationship between dose and total valproate concentration is nonlinear; concentration does not increase proportionally with the dose, but rather, increases to a lesser extent due to saturable plasma protein binding. The kinetics of unbound drug is linear.
Chronic non-bacterial osteomyelitis (CNO) is an autoinflammatory, osteolytic bone disorder sometimes localized to a unifocal site in the jaw, causing long-term pain and reduced function. The aim of this study was to describe the patients with CNO of the jaw, focusing on treatment with zoledronic acid for pain relief. An analysis of medical records of 24 patients with CNO of the jaw, including treatment with zoledronic acid and effects on pain relief. Descriptive statistics and nonparametric tests were used to describe the population and compare treatment effects, respectively. The average treatment period was 33.4 months (median 23; Q1 11.5; Q3 42.0) with an average of 4.1 infusions (median 3; Q1 2; Q3 5) of zoledronic acid. The average pain VAS score (visual analogue scale) was significantly reduced from 7.7 (median 8; Q1 6.5; Q3 8.5) to 2.5 points (median 2; Q1 0.5; Q3 4.5) (p < 0.001). At final visit, 46% of patients reported no pain and 38% reported a reduction of pain. At least 67% of patients had at least one episode of pain recurrence, and most patients experienced the first recurrence within a year of initial treatment. Four patients (16%) had no pain relief from the treatment. In this group of patients with CNO of the jaw, there was a positive response to treatment with zoledronic acid on pain relief, averaging 5.2 points on a pain VAS score, with 84% of patients treated experiencing either a partial or a total reduction in pain after about 2.5 years.
The present disclosure, in some embodiments, relates to a method of generating a prognosis for a patient. The method includes accessing automatically segmented pericoronary adipose tissue (PCAT) corresponding to a patient within an electronic memory. A plurality of non-confounding PCAT features are generated by measuring values of Hounsfield units for an imaging unit within the PCAT. The measured values of the Hounsfield units are predominately free of iodine confounding and artifacts. The plurality of non-confounding PCAT features are provided to a regression model. The regression model is configured to generate a prognosis for the patient using the plurality of non-confounding PCAT features